SynthesisFrontiers in aging neuroscience2025
Bibliometric analysis of global research on PD-L1/PD-1 pathway and neurodegenerative diseases over the last two decades (2004-2023).
Synthesis in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Reprogramming Neuroinflammation: Mitochondrial Targets and Immune Checkpoint Inhibitors in Alzheimer's Disease.Molecular neurobiology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Programmed death receptor 1 (PD-1), encoded by the PDCD1 gene, functions as a pivotal immunosuppressive molecule. Neurodegenerative diseases (NDDs) encompass a diverse array of neurological disorders that adversely impact the lives of millions of individuals globally. The current study discusses the impacts of PD-L1/PD-1 signaling on NDDs. Methods: A comprehensive online search was conducted using the Web of Science Core Collection database (WOSCC), with a limited time frame set from 2004 to 2023. Data were analyzed with CiteSpace, VOSviewer, and bibliometric package to explore trends in research output, key authors, institutions, journals, and thematic developments. Results: This study analyzed 366 publications within the field of PD-L1/PD-1 and NDDs. During 2004-2023, there's an overall upward trajectory in the number of publications as the years progressed. The United States has a significant influence in this field, accounting for the highest number of publications. It also boasts the top two authors, six of the top 10 journals, and four of the top five institutions in terms of article count. Keyword burst analysis identified EAE, Parkinson's disease, adaptive immunity, immune checkpoint blockade, and cerebrospinal fluid are research hotspots in recent years. Conclusion: This field has garnered increasing research attention, with the United States being the primary contributor. Recent studies have concentrated on the mechanisms through which PD-L1/PD-1 influences NDDs, and research into cerebrospinal fluid may persist as a focal point in the years to come. While the neuroprotective vs. neurodegenerative effects of PD-L1/PD-1 signaling remain controversial, this pathway represents a promising diagnostic and therapeutic target for NDDs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.